← Back to Search
IRGD-mediated Core-shell Nanoparticles Loading Carmustine And O6-benzylguanine For Glioma Therapy
C. Liu, S. Yao, Xuqian Li, F. Wang, Y. Jiang
Published 2017 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
Abstract iRGD (internalizing RGD) with high affinity to αν integrins was reported to enhance tumor penetrability by binding to neuropilin-1 (NRP-1). Based on our previous study, chitosan surface-modified poly (lactide-co-glycolides) nanoparticles (PLGA/CS NPs), loaded with carmustine (BCNU) and its sensitizer (O6-benzylguanine, BG) showed stronger anti-tumor effect than free drugs. In present study, PLGA/CS NPs (NPs) with core-shell structure were prepared and modified with iRGD or mPEG. F98, C6 or U87 cell lines with different receptors levels were selected for in vitro and in vivo studies. After administration of iRGD-mediated NPs, including iRGD-modified NPs (iRGD-NPs) and co-administration of iRGD and NPs (iRGD + NPs), their effects on glioma were compared with NPs. iRGD-NPs showed stronger cytotoxicity and cellular uptake than other groups. iRGD-NPs and iRGD + NPs displayed deeper tumor penetration and stronger anti-invasion effect on three dimensional (3D) glioma spheroids than NPs. On F98 glioma-bearing mice model, iRGD-mediated NPs showed enhanced crossing BBB ability and brain tumor accumulation levels. Correspondingly, the median survival time of iRGD + NPs, iRGD-NPs and NPs groups were 58, 49 and 34.5 days, respectively. Present studies supported the iRGD-mediated strategy to improve the efficacy of antitumor drug delivery system. Importantly, co-administration of iRGD may be a greater way over the conjugation of iRGD.
This paper references
Improved Brain Delivery of Benzylpenicillin with a Peptide-vector-mediated Strategy
C. Rousselle (2002)
Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelial-mesenchymal transition in vitro.
Sun-Ah Kim (2015)
Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain
A. Hamilton (2015)
Peptides as targeting elements and tissue penetration devices for nanoparticles.
E. Ruoslahti (2012)
Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy
B. Kaina (2010)
Transvascular delivery of small interfering RNA to the central nervous system
P. Kumar (2007)
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
F. Danhier (2012)
Tissue-penetrating delivery of compounds and nanoparticles into tumors.
K. Sugahara (2009)
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
F. Yuan (1995)
Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
J. Wiencke (1995)
Structure and design of polymeric surfactant-based drug delivery systems.
V. Torchilin (2001)
BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro.
H. Seong (2003)
Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Ke Wang (2014)
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel
R. Grossman (2015)
The RGD story: a personal account.
E. Ruoslahti (2003)
Specialization of tumour vasculature
E. Ruoslahti (2002)
Three-dimensional tissue culture models in cancer biology.
J. Kim (2005)
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
R. Schilsky (2000)
Effects of arginine‐glycine‐aspartic acid (RGD) containing snake venom peptides on parthenogenetic development and in vitro fertilization of bovine oocytes
K. L. White (2007)
The role of chemotherapy in the treatment of primary tumors of the central nervous system.
T. J. Moynihan (1994)
The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Guangzhi Gu (2013)
A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
D. Blumenthal (2014)
Nanostructured porous Si-based nanoparticles for targeted drug delivery
M. Shahbazi (2012)
Radioactive 198Au-Doped Nanostructures with Different Shapes for In Vivo Analyses of Their Biodistribution, Tumor Uptake, and Intratumoral Distribution
Kvar C. L. Black (2014)
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
S. Chowdhary (2015)
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
H. Zhang (2007)
New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.
Christian Ché (2010)
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection
Umar Akbar (2009)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
K. Sugahara (2010)
A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
Xingli Cun (2015)
Probing cellular mechanobiology in JU ST A CC EP TE D three-dimensional culture with collagen-agarose
TA Ulrich (2010)
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma
C. Ryan (2006)
Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: in vitro and in vivo evaluation.
Roonak Saadati (2014)
Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea].
E. Figueiredo (2010)
Microscale mechanisms of agarose-induced disruption of collagen remodeling.
Theresa A. Ulrich (2011)
Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
L. Qian (2013)
3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways.
P. DelNero (2015)
PEGylated nanoparticles for biological and pharmaceutical applications.
H. Otsuka (2003)
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
T. Tanaka (2004)
Therapeutic strategy for central nervous system tumors: present status, criticism and potential.
P. Paoletti (1984)
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas.
M. Hua (2011)
Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
R. Yang (2009)
Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices.
Theresa A. Ulrich (2010)
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
K. Temming (2005)
Simultaneous determination of O6-benzylguanine and 8-oxo-O6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography.
Traian Stefan (1997)
Modeling Tissue Morphogenesis and Cancer in 3D
K. Yamada (2007)
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Tambet Teesalu (2009)
RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells.
Saijie Zhu (2011)
Modeling tissue morphogenesis and cancer
KM Yamada (2007)
Delivery of temozolomide to the tumor bed via JU ST A CC EP TE D biodegradable gel matrices in a novel model of intracranial glioma with resection
U Akbar (2009)
Multicellular spheroids in ovarian cancer metastases: Biology and pathology.
K. Shield (2009)
Pore size variable type I collagen gels and their interaction with glioma cells.
Ya-li Yang (2010)
Mechanobiology in the Third Dimension
John A. Pedersen (2005)
This paper is referenced by
Targeted and theranostic applications for nanotechnologies in medicine
Saini Setua (2017)
Evaluation of anti-EGFR-iRGD recombinant protein with GOLD nanoparticles: synergistic effect on antitumor efficiency using optimized deep neural networks
A. C. Kaushik (2019)
Intravenously-injected gold nanoparticles (AuNPs) access intracerebral F98 rat gliomas better than AuNPs infused directly into the tumor site by convection enhanced delivery
H. Smilowitz (2018)
iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers
Houdong Zuo (2019)
Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells.
N. Ortiz (2020)
Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment
Y. Zhong (2019)
Nanoformulations for Therapeutics
P. S. Rao (2017)
Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs
Dirk van den Brand (2017)
Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Xuqian Li (2020)
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
S. Kang (2020)
Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: nanomedicine approaches to improve their efficacy.
J. Aparicio-Blanco (2020)
Contributions of immune cell populations in the maintenance, progression, and therapeutic modalities of glioma
Michael D. Caponegro (2018)
Multicellular Tumor Spheroids (MCTS) as a 3D In Vitro Evaluation Tool of Nanoparticles.
Hongxu Lu (2018)
Targeting Malignant Brain Tumors with Antibodies
Rok Razpotnik (2017)
Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review
J. Li (2020)
Design of an Amphiphilic iRGD Peptide and Self-Assembling Nanovesicles for Improving Tumor Accumulation and Penetration and the Photodynamic Efficacy of the Photosensitizer.
Yue Jiang (2018)
Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs)
M. Shevtsov (2018)